<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315571</url>
  </required_header>
  <id_info>
    <org_study_id>CXTIPSvLVP-v1</org_study_id>
    <nct_id>NCT04315571</nct_id>
  </id_info>
  <brief_title>Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents</brief_title>
  <official_title>Effective Ascites ReLief In earlY TIPS (EARLY TIPS) Using Viatorr CX vs. LVP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      For this study, the investigators will be collecting data based on patients' random selection
      to two different approved standard of care treatments for ascites: Subjects will get
      randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or
      Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      End Stage Liver Disease (ESLD) severely impacts body function leading to elevated blood
      pressure within the liver called &quot;portal hypertension.&quot; One of its subsequent symptoms is
      ascites, or fluid accumulation in the abdomen. One standard treatment to relieve ascites is
      large volume paracentesis (puncture of the abdomen to drain the fluid). Another standard
      treatment is the TIPS procedure, which involves creating a shunt (small passage allowing
      fluid movement) within the liver to relieve the increased blood pressure in the liver.

      For this study, the investigators will be collecting data based on patients' random selection
      to two different approved standard of care treatments for ascites: Subjects will get
      randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or
      Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.

      The study will include about 68 patients (34 patients will be selected for Group A:
      continuing conservative treatment of LVP with albumin infusion, and 34 patients will be
      selected for Group B: undergoing early TIPS with Gore®Viatorr®CX). Each patient will be
      followed up at 1 month, 3 months, 6 months, and 12 months.

      The primary objective of this study is to evaluate the overall clinical efficacy in symptom
      relief of ascites of patients receiving the Gore® Viatorr® CX in early TIPS procedures
      compared to LVP (large volume paracenthesis). In order to so, the investigators will be using
      information found in patient medical records, collected as a part of standard of care, to
      analyze clinical outcomes, complications, and the rate of secondary interventions at
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Paracentesis</measure>
    <time_frame>1 year post-procedure</time_frame>
    <description>The average number of paracentesis per week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant free survival</measure>
    <time_frame>1 year post-procedure or until the patient expires or receives transplant</time_frame>
    <description>Overall survival without transplant after the treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stent diameter change</measure>
    <time_frame>1 month and 6 months</time_frame>
    <description>Stent diameter changes from the time of TIPS placement</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Hypertension, Portal</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine Large Volume Paracentesis (LVP) with albumin infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gore® Viatorr® Endoprosthesis with controlled expansion</intervention_name>
    <description>TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>TIPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Large Volume Paracentesis with albumin infusion</intervention_name>
    <description>For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>LVP with albumin infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females &gt; 18 years of age at time of procedure

          -  First de novo TIPS placement

          -  Patent internal or external jugular vein

          -  Willing to provide the hepatology service information for follow up

          -  No known diagnosis of hypercoagulopathy

          -  No portal vein thrombosis

          -  No malignancy (must be a definite diagnosis)

          -  Patient must provide written informed consent

          -  Proper clinical indication of TIPS based on American Association for the Study of
             Liver Diseases (AASLD) guidelines

               -  Recurrent ascites necessitating at least 2 large volume paracenteses performed
                  within a minimum interval of 3 weeks

        Exclusion Criteria:

          -  Age &lt;18

          -  LVP &gt; 6 times in 2 months

          -  Liver failure (Child Pugh &gt; 12)

          -  Cardiac failure

          -  No right jugular venous access

          -  Absolute TIPS contraindications (e.g. right heart failure, severe encephalopathy,
             liver failure, pregnant (if possible)).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward W Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arineh Aghakhani</last_name>
    <phone>3102671268</phone>
    <email>aaghakhani@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saima Chaabane</last_name>
    <phone>3107948995</phone>
    <email>schaabane@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edward W Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Edward Wolfgang Lee, MD</investigator_full_name>
    <investigator_title>Associate Professor of Radiology and Surgery</investigator_title>
  </responsible_party>
  <keyword>end-stage liver disease</keyword>
  <keyword>hepatic encephalopathy</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

